anti-VEGF/Tie2 bispecific antibody (Aerpio Pharmaceuticals)

N/A

Report date: 2025/01/26 18:32:57

Base Information

Drug Nameanti-VEGF/Tie2 bispecific antibody (Aerpio Pharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTEK receptor tyrosine kinase agonistsVascular endothelial growth factor receptor antagonists

TargetsVascular endothelial growth factor receptorTEK receptor tyrosine kinase

Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesWhitehawk Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAadi Subsidiary Inc

Inactive CompaniesWhitehawk Therapeutics Inc

Active IndicationsDiabetic macular oedemaWet age-related macular degenerationNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A